Outcome of the Rights Issue

The subscription period in the Rights Issue ended on 13 April 2026. The Rights Issue comprised a maximum of 162,957,208 shares.

The outcome shows that 79,132,017 shares, corresponding to approximately 48.6 percent of the Rights Issue, have been subscribed for by exercise of subscription rights. In addition, 12,922,811 shares have been subscribed for without exercise of subscription rights, corresponding to approximately 7.9 percent of the Rights Issue. The Rights Issue is thereby subscribed to approximately 56.5 percent and guarantee commitments will be utilized to approximately 13.0 percent.

Through the Rights Issue, the Company will receive approximately 41.9 MSEK before issue costs.

Allotment of shares subscribed for without exercise of subscription rights

Allotment of shares subscribed for without exercise of subscription rights has been made in accordance with the principles stated in the information document that the Company published on 24 March 2026 in connection with the Rights Issue. Notification of such allocation will be made separately through a settlement note. Payment of subscribed and allotted shares shall be made through cash payment in accordance with the instructions in the settlement note. Nominee registered shareholders will receive notification on allocation in accordance with instructions from the respective nominee.

Changes in share capital and number of shares as well as dilution

Through the Rights Issue, the total number of shares in the Company will increase by 113,243,850 shares, which means that the total number of outstanding shares in the Company increases from 40,739,302 shares to 153,983,152 shares. The share capital increases by SEK 9,625,727.25, from SEK 3,462,840.67 to SEK 13,088,567.92. This corresponds to a dilution effect of approximately 73.5 percent of the total number of shares in the Company after the Rights Issue.

In addition to what is stated above, the potential issue of shares as compensation to guarantors may entail additional dilution.

Compensation for guarantee commitments

In connection with the Rights Issue, certain existing shareholders and a number of external investors have entered into guarantee commitments. According to the guarantee agreements, cash compensation is paid with 12 percent of the guaranteed amount, corresponding to a total of approximately SEK 3.7 million, or 14 percent of the guaranteed amount in the form of newly issued shares in the Company, with the same terms and conditions as for shares in the Rights Issue, including the subscription price in the Rights Issue.

If all guarantors were to choose to receive guarantee compensation in shares, a total maximum of 11,729,726 shares would be issued as guarantee compensation. The guarantors will inform whether they want to receive their compensation in cash or in shares no later than 20 April 2026.

The issue of shares as compensation to the guarantors is, if applicable, intended to be resolved by the Company’s Board of Directors based on the authorization granted by the extraordinary general meeting on 13 March 2026. Information about the issue resolution will, if applicable, be announced through a separate press release.

Trading in BTA

Trading in paid subscribed shares (BTA) is currently ongoing on Spotlight Stock Market under the short name BIBB BTA and will cease on 5 May 2026. Thereafter, BTA will be converted into shares. The shares will be admitted to trading on Spotlight Stock Market as soon as possible after conversion.

Resolution on Articles of Association

The extraordinary general meeting on 13 March 2026 resolved to change the provisions of the Articles of Association regarding the limits of the Company’s share capital and number of shares, and that the Board of Directors would be authorized to register the Company’s new Articles of Association according to one of three options (alternatively not to register any new Articles of Association at all) based on the outcome in the Rights Issue. Due to the outcome of the Rights Issue, the Board of Directors has decided to change the Articles of Association in accordance with option "B", i.e. the share capital shall be no less than SEK 9,928,000 and no more than SEK 39,712,000 and the number of shares shall be no less than 116,800,000 and no more than 467,200,000. The new Articles of Association will be registered with the Swedish Companies Registration Office in connection with the registration of the Rights Issue.

Advisers

Vator Securities acts as financial adviser and Foyen Advokatbyrå acts as legal adviser to the Company in connection with the Rights Issue. Nordic Issuing acts as issuing agent in connection with the Rights Issue.

This is a translation of the Swedish press release. In the event of any discrepancy, the Swedish language version shall prevail.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO

Email: fredrik.lindblad@bibbinstruments.com

Phone: +46 70 899 94 86

www.bibbinstruments.com 

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, DISCLOSURE OR PUBLICATION WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

This information is information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at the time specified by the Company''s news distributor at the time of publication of this press release.

About BiBBInstruments AB

BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. EndoDrill® enables tissue sampling with high precision and quality, with the aim of improving the diagnosis of several serious cancers, including those of the stomach, pancreas, liver, lungs, and bladder. BiBB’s product portfolio targets the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments - the most advanced and fastest-growing segment of endoscopy. In 2023, BiBB’s lead product EndoDrill® GI received 510(k) clearance from the U.S. FDA. In early 2024, CE marking was obtained under the new MDR regulatory framework for all three product variants: EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO. As a result, EndoDrill® became the first market-cleared powered endoscopic biopsy system in both the U.S. and Europe. EndoDrill® consists of sterile, single-use instruments paired with a dedicated drive system. BiBB was founded in 2013 by Dr. Charles Walther - cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital - and is headquartered at Medicon Village in Lund, Sweden. BiBB’s share (ticker: BIBB) is listed on the Spotlight Stock Market.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in BiBBInstruments in any jurisdiction, neither from BiBBInstruments nor from someone else.

This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an Information Document in the form provided for in Annex IX of the Prospectus Regulation before the subscription period in the Rights Issue began. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness. Vator Securities is acting for BiBBInstruments in connection with the Rights Issue and not for anyone else, and will not be responsible to anyone other than BiBBInstruments for providing the protections afforded to its clients or for giving advice in relation to the Rights Issue or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s and the group’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Spotlight Stock Market’s rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment").

Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channel.